Enfuvirtide

Nature Reviews Drug Discovery

Volumn 2, Issue 5, 2003, Pages 345-346

  LaBonte, Jason ^a   Lebbos, John ^a   Kirkpatrick, Peter ^b  

^a Decision Resources Inc   (United States)

^b Nature Reviews Drug Discovery   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR PHOSPHATE; ANION; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; CD4 IMMUNOGLOBULIN G2; CHEMOKINE RECEPTOR CCR5 INHIBITOR; EFAVIRENZ; ENFUVIRTIDE; INTEGRASE INHIBITOR; MARAVIROC; POLYMER; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SCH C; T 1249; TENOFOVIR; TIPRANAVIR; TNX 355; UNCLASSIFIED DRUG; VICRIVIROC; VIRUS RNA; GLYCOPROTEIN GP 41; PEPTIDE FRAGMENT;

ANTIBIOTIC RESISTANCE; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG MARKETING; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTHESIS; INJECTION SITE; LIFE CYCLE; MORTALITY; NOTE; PRIORITY JOURNAL; SKIN MANIFESTATION; VIREMIA; VIRUS CELL INTERACTION; VIRUS REPLICATION; ARTICLE;

ANTI-HIV AGENTS; HIV ENVELOPE PROTEIN GP41; HUMANS; PEPTIDE FRAGMENTS;

EID: 0038725575     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1091     Document Type: Note

References (5)

1. Lalezari, J. P. et al. Enfuvirtide, an HIV-1 fusion inhibitor for drug-resistant HIV infection in North and South America. N. Engl. J. Med. (2003) Mar 13 (doi: 10.1056/NEJMoa035026)
2. De Clercq, E. Strategies in the design of antiviral drugs. Nature Rev. Drug Discov. 1, 13-25 (2002).
3. Wild, C. T. et al. Peptides corresponding to a predictive α-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl Acad. Sci. USA 91, 9770-9774 (1994).
4. Kilby, J. M. et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nature Med. 4, 1302-1307 (1998).
5. FDA Drug Approvals List [online] (cited 28 March 2003) http://www.fda.gov/cder/foi/label/2003/021481lbl.pdf (2003).